IQuity's Breakthrough Autoimmune Technology
IQIsolate® is a suite of algorithms utilizing machine learning methods that analyze expression of RNA markers detected in a simple blood sample. IQuity has developed RNA-based diagnostic technologies for autoimmune disease and related disorders in neurology, gastroenterology and rheumatology, three specialties that serve a majority of autoimmune patients.
IQuity’s technology, IQIsolate analyzes RNA expression data from a blood sample to identify the presence or absence of disease at the cellular level. RNA expression is representative of presence of disease in real time, while changes in DNA indicate potential risk of disease. IQIsolate can distinguish among diseases in a given specialty – the gastroenterology panel can distinguish between irritable bowel syndrome (IBS) and inﬂammatory bowel disease (IBD). Within IBD, this technology can accurately distinguish Crohn’s from ulcerative colitis. The IQIsolate process takes one week and delivers results with greater than 90% accuracy.
IQuity is ﬁrmly committed to data transparency and scientiﬁc peer review, and will perform its tests in its independent CLIA certiﬁed lab.
“RNA-based diagnostics have the capability of providing highly accurate information that improves patient stratification. Measurements of RNA allow us to uncover a snapshot of gene activity in real time. This enables us to identify disease earlier than ever before. It is generally accepted that patients who get the right treatment sooner have improved long-term outcomes.”
Dr. Tom Aune, Chief Science Officer